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Reassessment Intervals for Transition From Low to High Fracture Risk
Among Adults Older Than 50 Years
William D. Leslie, MD, MSc; Suzanne N. Morin, MD, MSc; Lisa M. Lix, PhD; Patrick Martineau, MD, PhD; Mark Bryanton, MD; Eugene V. McCloskey, MD;
Helena Johansson, PhD; Nicholas C. Harvey, MD; John A. Kanis, MD
Abstract
IMPORTANCE Fracture risk scores are used to identify individuals at high risk of major osteoporotic
fracture or hip fracture for antiosteoporosis treatment. For those notmeeting treatment thresholds
at baseline, the optimal interval for reassessing fracture risk is uncertain.
OBJECTIVE To examine reassessment intervals for transition from low to high fracture risk under
guidelines-defined treatment thresholds.
DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included persons aged 50
years or older with fracture risk below treatment thresholds at baseline who had fracture risk
reassessed at least 1 year later. Data were obtained from a population-based bonemineral density
registry (baseline assessment during 1996-2015; reassessment to 2016) in the Province of Manitoba,
Canada. Primary analysis was performed fromMay to June 2019. Analysis for the revision was
performed in October 2019.
MAINOUTCOMES ANDMEASURES The primary outcomewas time to transition from low (below
the treatment threshold) to high fracture risk (treatment-qualifying risk score using osteoporosis
clinical practice guidelines strategies for Canada, the United States, and the United Kingdom).
RESULTS The study population consisted of 10 564 individuals (94.1%women; mean [SD] age at
baseline, 63.2 [8.2] years). At the time of reassessment (a mean [SD] interval of 5.2 [2.9] years
between initial and subsequent fracture risk assessment), 690 (6.6%) had reached the fixedmajor
osteoporotic fracture treatment threshold of 20%, 1546 (16.2%) had reached the fixed hip treatment
threshold of 3%, and 932 (9.4%) had reached the age-dependent major osteoporotic fracture
treatment threshold. Among those below 25% of the treatment threshold at baseline for each
guideline, few (0%-3.0%) reached guidelines-defined high fracture risk at follow-up. In contrast,
among those at the upper end of the scale for each guideline (75%-99% of the treatment threshold
at baseline), 30.6% to 74.4% reached guidelines-defined high fracture risk. An increased number of
clinical risk factors was associated with increased likelihood of reaching guidelines-defined high
fracture risk (range for 3 guidelines, 17.1%-28.2%) compared with unchanged or decreased clinical
risk factors (range for 3 guidelines, 3.3%-12.8%) (P < .001). Estimated time for 10% of the population
to reach treatment-qualifying high fracture risk ranged from fewer than 3 years tomore than 15 years.
CONCLUSIONS ANDRELEVANCE The findings suggest that baseline fracture risk (as a fraction of
the treatment threshold) and change in clinical risk factors can identify individuals with low and high
probability of guidelines-defined high fracture risk during follow-up, thereby potentially helping to
inform the reassessment interval.
JAMA Network Open. 2020;3(1):e1918954. doi:10.1001/jamanetworkopen.2019.18954
Key Points
Question What is the optimal
reassessment interval to detect high
fracture risk for those who do not meet
the treatment threshold at baseline?
Findings In this cohort study of 10 564
individuals, after amean interval of 5.2
years between initial and subsequent
fracture risk assessment, a range of
6.6% to 16.2% of the population
reached high fracture risk according to 3
guidelines-defined treatment
thresholds. Simple criteria, such as
baseline fracture risk as a fraction of the
treatment threshold and change in
number of clinical risk factors, were
associated with transition to high
fracture risk.
Meaning The findings suggest that
baseline fracture risk and change in
clinical risk factors can identify
individuals with low and high probability
of achieving a guidelines-defined
treatment threshold and potentially
help optimize the reassessment interval
in routine clinical practice.
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Introduction
Osteoporosis is characterized by susceptibility to fracture, with substantial health consequences for
the individual and society.1 Bonemineral density (BMD) is associated with fracture risk but has low
sensitivity, with most fractures occurring above the threshold for osteoporosis diagnosis (2.5 SDs
below peak bonemass; T-score, –2.5 or lower).2-4 Fracture risk prediction algorithms that incorporate
clinical risk factors independent of BMD have been developed to target high-risk individuals for
treatment. At present, the fracture risk assessment (FRAX) tool is themost widely used and has been
incorporated into more than 100 clinical practice guidelines.5 The FRAX tool evaluates 10-year risk
ofmajor osteoporotic fracture (MOF), defined as a composite of hip, clinical spine, distal forearm, and
proximal humerus, and 10-year risk of hip fracture based on age, sex, bodymass index, 7 additional
clinical risk factors, and (optionally) femoral neck BMD.6When used with BMD, the FRAX tool
provides a higher sensitivity than BMD alone.7
Repeated BMD testing is commonly performed, with a substantial proportion of women
receiving repeated tests within 2 years, a practice questioned by the ChoosingWisely campaign,8
speaking to the need for guidance to help clinicians make higher-value decisions regarding repeated
BMDmeasurement.8-10 Studies examining BMD loss and transition to osteoporosis have provided
insights into BMD testing intervals according to the level of baseline BMD.11 Subsequent analyses
have evaluated time to reach clinically relevant fracture risk for those who fall below the treatment
threshold at baseline12 and the doubling time in fracture risk,13 although these have not adequately
considered baseline fracture risk relative to the treatment threshold, which would be expected to
affect treatment eligibility. Specifically, one would expect a shorter interval for those just below the
treatment threshold and a longer interval for those well below the treatment threshold. Change in
clinical risk factors would also be expected to affect time to treatment qualification, with a shorter
interval for those with new clinical risk factors and a longer interval for those with a reduction in
clinical risk factors.
The current analysis was undertaken to examine reassessment intervals for transition from low
(below the treatment threshold) to treatment-qualifying high fracture risk in routine clinical practice.
We hypothesized that level of baseline risk relative to the treatment threshold and change in clinical
risk factors are associated with the time to reach a treatment-qualifying high-risk level. Because
treatment guidelines differ among countries and this may be associated with results, we examined 3
different osteoporosis practice guideline strategies for pharmacologic treatment thresholds: (1) fixed
MOFwith 10-year risk of 20% or greater (major determinant in Canadian guidelines14), (2) fixed hip
fracture with 10-year risk of 3% or greater (major determinant under US National Osteoporosis
Foundation guidelines15), and (3) an age-dependent threshold that plateaus after age 70 years
corresponding to theMOFwith 10-year risk for a womanwho has already sustained a fragility
fracture (major determinant according to the UK National Osteoporosis Guideline Group16).
Methods
Study Population
We performed a provincial registry-based cohort study to examine change in fracture risk score and
treatment threshold qualification for individuals aged 50 years or older at the time of an initial
fracture risk assessment including BMD (January 1, 1996, throughMarch 31, 2015) and fracture risk
reassessed 1 or more year later (extending to March 31, 2016). The study was approved by the
Research Ethics Board of the University of Manitoba; data access was approved by the Health
Information Privacy Committee of Manitoba Health; and the need for informed consent was waived
in accordance with the Personal Health Information Act of Manitoba. The anonymized data extract
used for this work was approved and created in 2018, and primary data analysis was completed from
May to June 2019. Analysis for the revision was performed in October 2019. This study followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.17
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In Manitoba, Canada, dual energy x-ray absorptiometry (DXA)–based BMD testing is managed
as an integrated clinical program.18 The programmaintains a database of all DXA results, which can
be linked with other provincial population-based computerized health databases through an
anonymous personal identifier. The DXA database has completeness and accuracy in excess of
99%.19 Scans obtained before 1996were excluded because of absence of at least 1 year of pharmacy
data before entry. We excluded (1) nonresidents of the province, (2) individuals younger than 50
years at initial assessment, (3) those without femur neck BMD test data or other data required to
calculate FRAX risk score at the initial assessment to subsequent reassessment, (4) those who
received treatment (defined as a prescription of >3months of oral or parenteral bisphosphonate,
raloxifene, denosumab, calcitonin, teriparatide, or systemic estrogens), (5) those with a previous hip
or spine fracture, and (6) those already qualifying as having reached a treatment-qualifying fracture
risk threshold at the time of initial scan using the previous clinical practice guideline definitions.
BoneMineral DensityMeasurements and Fracture Risk
Hip DXA scans were performed and analyzed in accordance with manufacturer recommendations.
Femoral neck T-scores (number of SDs above or below young adult mean BMD) were calculated from
the third National Health and Nutrition Examination Survey (NHANES III; 1988-1994) white female
reference values for fracture risk assessment following national and international guidelines.14,20-22
All reporting physicians and supervising technologists are required tomaintain DXA certification with
the International Society for Clinical Densitometry. The program’s quality assurance is under strict
supervision by a medical physicist.18 The cross-calibrated instruments used for this study (1 DPX, 3
Prodigy, and 3 iDXA; GE/Lunar Healthcare) (between-scanner differences, <0.1 T-score) exhibited
stable long-term performance (coefficient of variation, <0.5%). Short-term reproducibility
(coefficient of variation) for femoral neck BMD from themultiple technologists was 2.3% (>400
repeated hip DXA scans performedwithin 28 days).
The 10-year risk of MOF and hip fracture risk were calculated using the fracture risk assessment
tool, Canadian version (FRAX DesktopMulti-Patient Entry, version 3.7; Osteoporosis Research
Limited), which was calibrated using nationwide hip fracture andmortality data.23,24 Predictions
agree closely with observed fracture risk in our population.25,26 In brief, age, bodymass index,
femoral neck BMD, and other data required for calculating fracture risk with the FRAX tool were
assessed from on-site measurements (height and weight) and information collected directly from
individuals through the intake questionnaire at the time of each DXA scan.27Questionnaire
informationwas supplementedwith population-based health care data (hospital discharge abstracts,
medical claims diagnoses, and provincewide retail pharmacy database) as recently described,
thereby ensuring complete information for almost all individuals.28 All fracture risk scores included
BMD because this more accurately assesses fracture risk than do clinical risk factors or BMD alone
and because there is no significant cost or limitation to repeating fracture risk scores based on clinical
risk factors alone.7 If clinical risk factors changed between the initial fracture risk assessment and
subsequent fracture risk reassessment, this was incorporated in the fracture risk scores.
Outcomes
The primary outcome was time to transition from below the treatment threshold to a treatment-
qualifying high fracture risk score according to the 3 osteoporosis clinical practice guidelines’
strategies: fixedMOF threshold of 20%, fixed hip threshold of 3%, and age-dependent MOF
threshold.14-16 Analyses were stratified according to how close (or far) the initial fracture risk
measurement was from the treatment threshold. This was operationalized as the fraction of the
treatment threshold at baseline (<25%, 25%-49%, 50%-74%, and 75%-99%).
Statistical Analysis
Descriptive statistics for demographic and baseline characteristics are presented as mean (SD) for
normally distributed continuous variables, median (interquartile range [IQR]) for continuous
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variables with a nonnormal distribution, or number (percentage) for categorical variables. Therewere
nomissing data for the analytic cohort. Parametric (t tests) and nonparametric (Mann-Whitney test,
χ2 test) methods were used to compare population characteristics according to subsequent
treatment threshold qualifications. The Cochran-Armitage test was used to test for linear trend in
reaching high fracture risk according to baseline risk categories. We examined the absolute and
relative change in MOF and hip fracture risk over time according to change in the number of FRAX
clinical risk factors (decrease, no change, or increase). Loess curve smoothing was performed and
curves interpolated to 0.1-year increments. Kaplan-Meier curves were used to construct the
cumulative incidence of reaching high fracture risk according to fraction of treatment threshold at
baseline (<25%, 25%-49%, 50%-74%, and 75%-99%), and groups were compared using the
log-rank test. Cox proportional hazards regressionmodels were used to estimate time in years (with
95% CIs) for 10% of the population to reach the treatment threshold according to fraction of the
treatment threshold at baseline and change in number of FRAX clinical risk factors (minimum of 1
year andmaximum of 15 years at 0.1-year increments). Model covariates included fraction of
treatment threshold at baseline, change in the number of FRAX clinical risk factors, and the 2-way
interaction term of these variables. The proportional hazards assumptions were tested and
confirmed by examining Schoenfeld residuals. The choice of 10% for transition to the treatment
threshold was selected based on similar previous analyses.11,12 Separate analyses were conducted for
the 3 different treatment strategies described previously. In sensitivity analyses, time for 5%, 20%,
or 50% of the population to reach the treatment threshold was modeled, and change in the number
of FRAX clinical risk factors was substratified as an increase of 1 vs 2 ormore. Statistical analyseswere
performedwith Statistica, version 13.0 (StatSoft Inc) and curve smoothing with figure generation
using Sigmaplot, version 13.0 (Systat Software Inc). A 2-sided P  .05 indicated statistical
significance.
Results
The study population selection process is summarized in Figure 1. The analytic cohort consisted of
10 564 individuals contributing to 1 or more of the treatment paradigms: 10 532 fixed MOF, 9541
fixed hip, and 9956 age-dependent MOF. The mean (SD) age at baseline was 63.2 (8.2) years, and
94.1%were women. Median baseline MOF risk was 7.0% (IQR, 5.2%-9.8%), andmedian baseline hip
fracture risk was 0.7% (IQR, 0.3%-1.5%).
Figure 1. Flowchart of Individuals in the Cohort
86 711 Baseline DXA scans, 1996-2015
10 564 Overall analytic cohort
9541 Hip 3% criterion: below
threshold at baseline
10 532 MOF 20% criterion: below
threshold at baseline
690 Above threshold at follow-up 1546 Above threshold at follow-up 932 Above threshold at follow-up
9956 MOF NOGG criterion: below
threshold at baseline
76 147 Exclusions
49 588 No follow-up scan
11 558 Received treatment
11 144 Age <50 y
1960 Incomplete FRAX data
1285 Nonresident
318 High risk at baseline
all criteria
294 Previous hip or spine
fracture
DXA indicates dual-energy x-ray absorptiometry;
FRAX, fracture risk assessment; MOF, major
osteoporotic fracture; and NOGG, National
Osteoporosis Guideline Group.
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Themean (SD) interval between initial fracture risk assessment and subsequent assessmentwas
5.2 (2.9) years. At the timeof reassessment, 690 individuals (6.6%)had reached the fixedMOF treat-
ment threshold of 20%, 1546 (16.2%) had reached the fixedhip treatment threshold of 3%, and932
(9.4%)had reached the age-dependentMOF treatment threshold (Table 1).Medianbaseline fracture
risk, as a fraction of the treatment threshold,was significantly greater among thosewho subsequently
reached the treatment threshold and adesignation of high fracture risk than among thosewhodid not
(fixedMOF treatment threshold: 0.69 [IQR,0.52-0.85] vs0.34 [IQR,0.25-0.46]; fixed hip treatment
threshold: 0.60 [IQR,0.39-0.77] vs0.15 [IQR,0.07-0.30]; age-dependentMOF treatment threshold:
0.70 [IQR,0.56-0.86] vs0.49 [IQR,0.43-0.60]; allP < .001). Over time, therewas an increase in the
total number of clinical risk factors, and thiswas significantly greater for thosewith transition to
treatment-qualifying fracture risk than among thosewithout (fixedMOF treatment threshold: 60.1%vs
20.4%; fixedhip treatment threshold: 40.4%vs 19.8%; age-dependentMOF treatment threshold:
69.5%vs 18.8%; allP < .001).
Table 1. Characteristics of the Study Population
Characteristic
Overall
(N = 10 564)
Threshold at Follow-up
Reached Fixed MOF Threshold of 20% Reached Fixed Hip Threshold of 3% Above Age-Dependent MOF
No
(n = 9842)
Yes
(n = 690) P Value
No
(n = 7995)
Yes
(n = 1546) P Value
No
(n = 9024)
Yes
(n = 932) P Value
Age, mean (SD), y 63.2
(8.2)
62.8
(8.0)
69.7
(8.2)
<.001 61.0
(7.1)
67.7
(6.8)
<.001 63.3
(8.0)
65.5
(10.0)
<.001
Women, No. (%) 9941
(94.1)
9232
(93.8)
677
(98.1)
<.001 7561
(94.6)
1466
(94.8)
.69 8466
(93.8)
902
(96.8)
<.001
Body mass index,
mean (SD)a
27.4
(5.3)
27.4
(5.3)
26.8
(4.6)
.003 27.7
(5.4)
27.0
(4.8)
<.001 27.6
(5.3)
26.4
(4.8)
<.001
Previous fracture,
No. (%)
783
(7.4)
600
(6.1)
159
(23.0)
<.001 435
(5.4)
185
(12.0)
<.001 420
(4.7)
129
(13.8)
<.001
Parental hip fracture,
No. (%)
733
(6.9)
608
(6.2)
93
(13.5)
<.001 523
(6.5)
131
(8.5)
.006 318
(3.5)
91
(9.8)
<.001
Smoker,
No. (%)
681
(6.4)
613
(6.2)
67
(9.7)
<.001 406
(5.1)
125
(8.1)
<.001 534
(5.9)
71
(7.6)
.04
Recent glucocorticoid use,
No. (%)
506
(4.8)
464
(4.7)
38
(5.5)
.35 357
(4.5)
64
(4.1)
.57 353
(3.9)
48
(5.2)
.07
Rheumatoid arthritis,
No. (%)
223
(2.1)
191
(1.9)
26
(3.8)
.001 147
(1.8)
45
(2.9)
.006 140
(1.6)
32
(3.4)
<.001
Secondary osteoporosis,
No. (%)
1780
(16.8)
1694
(17.2)
83
(12.0)
<.001 1427
(17.8)
200
(12.9)
<.001 1544
(17.1)
133
(14.3)
.03
High alcohol use,
No. (%)
25
(0.2)
S
(<1.0)
S
(<1.0)
.61 S
(<1.0)
S
(<1.0)
.34 S
(<1.0)
S
(<1.0)
.04
Femur neck T-score,
mean (SD)
−1.2
(0.8)
−1.2
(0.8)
−1.9
(0.6)
<.001 −1.0
(0.8)
−1.7
(0.5)
<.001 −1.1
(0.8)
−1.8
(0.6)
<.001
Baseline 10-y MOF risk,
median (IQR), %b
7.0
(5.2-9.8)
6.8
(5.1-9.2)
13.8
(10.3-17.0)
<.001 6.2
(4.7-7.9)
9.9
(8.2-11.7)
<.001 6.6
(5.0-8.9)
9.7
(6.7-14.7)
<.001
Baseline 10-y hip fracture
risk, median (IQR), %
0.7
(0.3-1.5)
0.6
(0.3-1.3)
3.0
(1.5-4.6)
<.001 0.5
(0.2-0.9)
1.8
(1.2-2.3)
<.001 0.6
(0.2-1.3)
1.6
(0.6-3.7)
<.001
Interval, mean (SD), yb 5.2
(2.9)
5.1
(2.9)
6.3
(3.2)
<.001 5.0
(2.8)
6.4
(3.3)
<.001 5.1
(2.9)
5.9
(3.2)
<.001
Baseline MOF risk
as fraction of fixed 20%
threshold, median (IQR)b
0.35
(0.26-0.49)
0.34
(0.25-0.46)
0.69
(0.52-0.85)
<.001 0.31
(0.24-0.40)
0.49
(0.41-0.58)
<.001 0.33
(0.25-0.45)
0.49
(0.34-0.73)
<.001
Baseline hip fracture risk
as fraction of fixed 3%
threshold, median (IQR)b
0.19
(0.08-0.40)
0.18
(0.08-0.38)
0.51
(0.29-0.74)
<.001 0.15
(0.07-0.30)
0.60
(0.39-0.77)
<.001 0.17
(0.08-0.37)
0.29
(0.14-0.54)
<.001
Baseline MOF risk as fraction
of age-dependent MOF
threshold, median (IQR)b
0.50
(0.43-0.63)
0.50
(0.43-0.61)
0.75
(0.59-0.88)
<.001 0.48
(0.42-0.57)
0.57
(0.49-0.66)
<.001 0.49
(0.43-0.60)
0.70
(0.56-0.86)
<.001
Clinical risk factors,
No. (%)
Decrease 679
(6.4)
652
(6.6)
22
(3.2)
<.001 512
(6.4)
58
(3.8)
<.001 531
(5.9)
23
(2.5)
<.001
Increase 2430
(23.0)
2012
(20.4)
415
(60.1)
<.001 1585
(19.8)
624
(40.4)
<.001 1701
(18.8)
648
(69.5)
<.001
Abbreviations: IQR, interquartile range; MOF, major osteoporotic fracture; S, suppressed
small numbers.
a Calculated as weight in kilograms divided by height in meters squared.
b Major osteoporotic fracture and hip fracture risk were computed using the fracture risk
assessment tool with bonemineral density.
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For those below25%of the treatment threshold at baseline, few (range, 0%-3.0% for 3 guide-
lines) reached guidelines-definedhigh fracture risk at follow-up (eTable 1 in the Supplement). In con-
trast, for those at the upper endof the scale (75%-99%of the treatment threshold at baseline), 30.6%
(age-dependentMOF threshold), 45.4% (fixed 10-yearMOF threshold) and 74.4% (fixed 10-year hip
fracture risk threshold) reached guidelines-definedhigh fracture risk. Therewas a statistically signifi-
cant linear trend for overall change in clinical risk factors according to increasing fraction of treatment
threshold at baseline (fixedMOF treatment threshold: 0.7% [<25% threshold], 2.5% [25%-49%
threshold], 13.3% [50%-74%threshold], 45.4% [75%-99%threshold]; fixed hip treatment threshold:
3.0%, 18.7%, 47.8%, and 74.4%; age-dependentMOF treatment threshold: 0%, 10.9%, 30.6%, and
30.6%; allP < .001 for trend). An increase in the number of clinical risk factorswas associatedwith in-
creased likelihoodof reaching guidelines-definedhigh fracture risk (range, 17.1%-28.2% for 3 guidelines)
comparedwith a stable or decreasednumber of clinical risk factors (range, 3.3%-12.8% for 3 guidelines)
(P < .001). Change in number of clinical risk factorswas independently associatedwith the likelihoodof
reaching guidelines-definedhigh fracture risk at follow-up,with a statistically significant linear trend in
all baseline risk categories except for those less than 25%of the age-dependentMOF treatment thresh-
old at baseline because noone reached the treatment threshold.
Figure 2 shows a gradual absolute and relative increase in fracture risk with increasing time
interval, with a similar trend seen for individuals with a decrease, no change, or increase in clinical risk
Figure 2. Major Osteoporotic Fracture (MOF) and Hip Fracture Risk Changes for Intervals Between Fracture Risk Assessments According to Change in the Number of
Clinical Risk Factors
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factors. The time to doubling in MOF risk was modified by change in the number of clinical risk
factors. For individuals with a decrease or no change in the number of clinical risk factors, the time to
high fracture risk exceeded 15 years and was 8.2 years when there was an increase in the number of
clinical risk factors. For hip fracture risk, the doubling timewas 7.7 years when there was a decrease in
the number of clinical risk factors, 5.9 years when there was no change, and 2.3 years when there
was an increase in the number of clinical risk factors.
The cumulative fraction of the population reaching high fracture risk was associated with
baseline risk category for each of the 3 different treatment strategies, with shorter time to reach high
fracture risk for those closer to the treatment threshold (Figure 3). The reassessment interval based
on time for 10% of the population to reach guidelines-defined high fracture risk from the Cox
proportional hazards regressionmodels is summarized in Table 2. Greater baseline fracture risk and
an increased number of clinical risk factors were associated with a shorter interval, whereas lower
baseline fracture risk and a reduction in clinical risk factors were associated with an increased time
interval to high fracture risk. For the fixed MOF treatment threshold, those with baseline risk less
than 25% of the treatment threshold were unlikely to transition to guidelines-defined high fracture
risk within the first 15 years. Even when there was an increase in the number of clinical risk factors, a
cumulative fraction high risk of 13.3 years (95% CI, 11.9-14.5 years) was required for 10% of the
population to reach high risk. Conversely, for individuals close to the treatment threshold
(75%-99%), time for 10% of the population to reach high fracture risk was from 3 to 4 years even
Figure 3. Cumulative Fraction of the Population Reaching High Fracture Risk According to Fraction of Treatment Threshold at Baseline
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Dashed line indicates point where 10% of the population reached high fracture risk.
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when there was a decrease in the number of clinical risk factors. Intermediate results were seen for
the other scenarios. For fixed hip fracture treatment threshold, transition times were generally
shorter, whereas for the age-dependent MOF treatment threshold, transition times were generally
longer. Reassessment intervals for 5%, 20%, and 50% of the population to reach guidelines-defined
high fracture risk are given in eTables 2-4 in the Supplement.
Additional analyses showed that a greater increase in the number of clinical risk factors (2 vs
1) had an association with reaching guidelines-defined high fracture risk (eTable 5 in the
Supplement). For those with an increase in the number of clinical risk factors of 2 or more, the time
to doubling in MOF risk was 1.5 years, and for hip fracture risk, the time to doubling in MOF risk was
less than 1 year (eFigure 1 in the Supplement). Age and sex, which were already considered in the
baseline risk, made a negligible independent contribution in estimating reassessment intervals for
transition to clinically relevant high fracture risk (eFigure 2 in the Supplement).
Discussion
This analysis of a population-based clinical registry of individuals undergoing baseline and
subsequent fracture risk assessment found that relatively few individuals (<20%) reached
guidelines-defined high fracture risk after a mean (SD) of 5.2 (2.9) years (ranging from 6.6% for fixed
MOF treatment threshold to 16.2% for fixed hip fracture threshold). Major variables associatedwith
reaching treatment-qualifying fracture risk were the baseline level of risk (particularly when FRAX
scores were 75%-99% of the treatment threshold) and an increase in the number of clinical risk
factors. Together, thesemeasures identified subgroups in which transition to guidelines-defined high
fracture risk was unlikely for more than 15 years and others in which transition to high risk occurred
before 3 years. Broadly similar patterns were seen for fracture risk strategies and thresholds that are
included in the clinical practice guidelines for Canada, the United States, and the
United Kingdom.14-16
Simulation analysis performed by Reid and Gamble13 found a doubling time in 10-year hip
fracture risk of 5 to 6 years across a range of baseline assumptions, with a doubling time for 10-year
MOF risk that exceeded 10 years. Gourlay et al11 analyzed the time for 10% of women who did not
have osteoporosis at baseline to make the transition to osteoporosis. The estimated testing interval
was 16.8 years for women with normal BMD and as short as 1.1 years for women with advanced
Table 2. Time for 10%of the Population to Reach High Fracture Risk According to Fraction of Treatment
Threshold at Baseline and Change in Clinical Risk Factors
Change in Clinical
Risk Factors
Baseline Threshold, Time to Threshold (95% CI), ya
<25% 25%-49% 50%-74% 75%-99%
Fixed MOF Threshold of 20%
Decrease >15 (>15 to >15) >15 (14.5 to >15) 8.6 (6.7 to 13) 4.1 (3.6 to 5.5)
No change >15 (>15 to >15) >15 (>15 to >15) 7.1 (6.5 to 8.1) 2.9 (2.9 to 3.2)
Increase 13.3 (11.9 to 14.6) 7.1 (6.6 to 7.7) 3.5 (3.3 to 3.7) 2.9 (2.8 to 3.2)
Overall >15 (14.6 to >15) 11.4 (10.3 to 12.3) 4.9 (4.7 to 5.4) 3.1 (2.9 to 3.3)
Fixed Hip Fracture Threshold of 3%
Decrease 14.9 (13.1 to >15) 6.4 (5.3 to 8.4) 3.5 (3.2 to 4.3) 3.1 (2.9 to 3.7)
No change 14.9 (14.1 to 14.9) 5.5 (5.2 to 5.9) 3.2 (3.1 to 3.3) 2.7 (2.6 to 2.9)
Increase 8.1 (7.5 to 8.8) 3.6 (3.4 to 3.8) 3.1 (2.9 to 3.2) 3.0 (2.9 to 3.1)
Overall 11.2 (10.6 to 11.7) 4.6 (4.4 to 4.9) 3.2 (3.1 to 3.3) 2.8 (2.8 to 2.9)
Age-dependent MOF Threshold
Decrease >15 (>15 to >15) >15 (>15 to >15) 10.4 (7.4 to 14.9) 5.2 (4.3 to 7.4)
No change >15 (>15 to >15) >15 (>15 to >15) 12.9 (11.8 to 14.7) 3.4 (3.2 to 3.6)
Increase >15 (>15 to >15) 6.8 (6.1 to 7.7) 3.3 (3.2 to 3.5) 2.8 (2.6 to 2.9)
Overall >15 (>15 to >15) 12.6 (11.8 to 13.6) 5.4 (5.1 to 5.7) 3.3 (3.2 to 3.5)
Abbreviation: MOF, major osteoporotic fracture.
a More than 15 indicates that less than 10% of the
population reached high fracture risk by 15 years.
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osteopenia (BMD T-score, –2.00 to –2.49). A subsequent study extended these observations to
examine the time for 10% of women to develop a treatment-level fracture risk score using US
National Osteoporosis Foundation guidelines.12 Before age 65 years, postmenopausal womenwith a
subthreshold fracture risk score at baseline rarely developed a treatment-level FRAX score. Time to
a treatment-level score ranged from 7.6 years (ages 65-69 years) to 5.1 years (ages 75-79 years). Our
study showed that estimated time to develop a treatment-level high fracture risk score was
associated with baseline fracture risk and new clinical risk factors.
Limitations
This study has limitations. Because the study population was derived from a clinical registry, the
decision to reassess fracture risk was influenced by clinician and patient perception of an individual’s
risk for fractures. However, thismay have increased the relevance of our study to the clinical practice
setting where such considerations are a standard part of patient care and decision-making because
research cohorts may not reflect routine clinical practice.29 Our study did not consider competing
mortality. We excluded individuals receiving pharmacologic treatment and those with previousmajor
fracture (hip or clinical vertebral), which other researchers have addressed through a competing risk
analysis12; the objective of this study was to examine the change in fracture risk in the absence of
treatment (which would affect BMD loss) and those with previous hip or clinical vertebral fracture
(generally recommended for treatment rather than further risk assessment). Our analysis of change
in clinical risk factors did not consider their different weights in the FRAX tool because this can be
directly modeled through the website. Also, the population was 98%white or of European ancestry,
and the lack of racial/ethnic heterogeneity precluded a direct assessment of whether this modified
our findings. Likewise, international FRAXmodels reflect underlying population differences in terms
of fracture andmortality rates. The generalization of our findings to other populations and FRAX
models is uncertain.
Conclusions
The findings suggest that baseline fracture risk (as a fraction of the treatment threshold) and number
of clinical risk factors can identify individuals with low and high probability of guidelines-defined high
fracture risk during follow-up. This could potentially help to inform the reassessment interval.
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eTable 1.Number (Percent) Reaching High Fracture Risk at Follow-up According to Fraction of Treatment
Threshold at Baseline and Change in Number of Clinical Risk Factors (CRFs)
eTable 2. Time in Years (95% CI) for 5% of the Population to Reach High Fracture Risk According to Fraction of
Treatment Threshold at Baseline and Change in Number of Clinical Risk Factors (CRFs)
eTable 3. Time in Years (95% CI) for 20% of the Population to Reach High Fracture Risk According to Fraction of
Treatment Threshold at Baseline and Change in Number of Clinical Risk Factors (CRFs)
eTable 4. Time in Years (95% CI) for 50% of the Population to Reach High Fracture Risk According to Fraction of
Treatment Threshold at Baseline and Change in Number of Clinical Risk Factors (CRFs)
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eTable 5.Number (Percent) Reaching High Fracture Risk at Follow-up According to Fraction of Treatment
Threshold at Baseline and Change in Number of Clinical Risk Factors (CRFs) Stratified as Decreases (–1), No Change
(0), or Increase (+1, +2, or More)
eFigure 1. Absolute and Relative Change in Major Osteoporotic Fracture (MOF) Risk and Hip Fracture Risk for
Increasing Intervals Between Fracture Risk Assessments According to Change in the Number of Clinical Risk
Factors (CRFs) Stratified as Decrease (–1), No Change (0), or Increase (+1, +2 or More)
eFigure 2. Importance of Variables Predicting Transition to High Fracture Risk According to Fixed 20%Major
Osteoporotic Fracture (MOF) Risk, Fixed 3%Hip Fracture Risk, and Age-dependent MOF Risk
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